Phaseline

Companies › Riboscience

Riboscience: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 2 Phase 2, 1 Phase 1; Oncology; next expected readout Apr 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
RBS2418
Ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1) inhibitor that increases cGAMP
ENPP1Phase 2Advanced Unresectable Hepatocellular Carcinoma; Metastatic Colorectal Cancer; Advanced CancerApr 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07175441RBS2418Phase 2Advanced Unresectable Hepatocellular CarcinomaOncologyApr 2027
NCT05270213RBS2418Phase 1Advanced CancerOncologyApr 2027
NCT06824064RBS2418Phase 2Metastatic Colorectal CancerOncologyDec 2027

Targets

ENPP1 (1)

Companies with the same targets

Colgate Palmolive Stingray Therapeutics Inozyme Pharma

Companies built like this

iOnctura Toray Industries SynerGene Therapeutics Lyvgen Biopharma Holdings Imvax

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.